Adjusted per-share earnings in the fourth quarter for UnitedHealth top analysts’ estimates but revenue comes up short.

The UnitedHealth Group is overcharging patients for necessary life-saving drugs as a result of price gouging that increases the cost of such medication exponentially.

Witty's comments came during the company's first earnings call since the killing of Brian Thompson, the CEO of the company's insurance arm UnitedHealthcare.

Between 2017 and 2022, UnitedHealth Group’s Optum, Cigna’s Express Scripts and CVS Health’s CVS Caremark marked up their prices by hundreds — and in some cases, thousands — of percent, resulting in $7.3 billion in revenue above cost.

UnitedHealth Group (NYSE:UNH) reported the fourth-quarter 2024 earnings and reaffirmed 2025 guidance. The company reported adjusted EPS of $6.81, up from $6.16 a year ago, beating the consensus of $6.

But high medical costs contributed to results that disappointed Wall Street, and the company’s stock fell on the news that it had made less than analysts expected.

From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.

UnitedHealth Group Inc. operates the nation’s largest health insurer ... Shares of other other health care conglomerates like CVS Health and Cigna also were down.

Discover how the three largest pharmacy benefit managers are rejecting biosimilars from their formularies, except for their own private-label drugs.

The share of in-network federal health insurance exchange plan claims denied in 2023 was the highest since 2015, according to a KFF analysis.

UnitedHealth Group Inc.'s $69 million class settlement over the Wells Fargo & Co. target date funds offered by its 401(k) plan received initial court approval.

A new report finds Eden Prairie-based UnitedHealth Group and two Blue Cross Blue Shield nonprofit insurers had the highest claim-denial rates among individual market health plans sold in 2023 on the federal government’s HealthCare.